Nasal and nasal-type natural killer/T-cell lymphoma

S. Hirakawa, M. Kuyama, S. Takahashi, O. Yamasaki, H. Kanzaki, T. Teshima, M. Harada, Y. Ma, T. Kawabata, T. Yoshino, J. Arata

Research output: Contribution to journalArticlepeer-review

37 Citations (Scopus)

Abstract

Nasal and nasal-type natural killer (NK)/T-cell lymphomas follow an aggressive course and have a poor prognosis. Recent pathologic studies suggest that the disease is a malignant proliferation of NK cells, which often express CD56. An association with the Epstein-Barr virus has also been reported. Skin involvement occurred in each of the 3 patients studied. Radiation therapy provided some benefit to the patients in the early stages. Conventional chemotherapies were not effective. To overcome this multiple- drug resistance of the tumor cells, cyclosporine and high-dose chemotherapy was combined with peripheral-blood stem-cell transplantation. The average life span from the onset of the disease for our patients was 9.6 months. Further improvement in the management of nasal and nasal-type NK/T-cell lymphomas is necessary.

Original languageEnglish
Pages (from-to)268-272
Number of pages5
JournalJournal of the American Academy of Dermatology
Volume40
Issue number2 I
DOIs
Publication statusPublished - Jan 1 1999

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Nasal and nasal-type natural killer/T-cell lymphoma'. Together they form a unique fingerprint.

Cite this